

Supplementary Table 1: Clinical evidence of widely used probiotics from meta-analysis or randomized controlled trials (RCT) for *H. pylori* eradication (only studies that involved a single probiotic were included).

Probiotic	Study type	Interventions		Sample size		Eradication rate		OR/RR (95%CI)	Author
		Probiotic	Control	Probiotic	Control	Probiotic	Control		
<i>Lactobacillus</i>	Meta analysis	Standard triple therapy + <i>Lactobacillus</i>	Standard triple therapy	483	489	80.3%	69.1%	1.16 (1.08, 1.25)	Yu <i>et al.</i> ¹
<i>L. acidophilus</i>	RCT	Standard triple therapy + <i>L. acidophilus</i>	Standard triple therapy	31	31	83.9%	80.6%	NA	Medeiros <i>et al.</i> ²
	RCT	Standard triple	Standard triple	59	58	88.0%	72.0%	NA	

<i>L. reuteri</i>	Meta analysis	therapy + inactivated	therapy						<i>et al.</i> ³	
		<i>L. acidophilus</i>								
		Standard triple	Standard triple							
		therapy, bismuth-	therapy, bismuth-							
		quadruple therapy, or sequential therapy +	quadruple therapy, or sequential	544	543	81.8%	75.0%	NA	Li <i>et al.</i> ⁴	
<i>L. casei</i>	RCT	<i>L. reuteri</i>	therapy + placebo							
		Standard triple	Standard triple						Sahagún-	
		therapy + inactivated	therapy	31	33	94.0%	76.0%	NA	Flores <i>et al.</i> ⁵	
		<i>L. casei</i>								
		Standard triple	Standard triple	34	32	97.05%	93.75%	NA	Tursi <i>et al.</i> ⁶	
		therapy + inactivated	therapy							

		<i>L. casei</i>							
		Bismuth-containing	Bismuth-containin						
<i>Clostridium</i>	RCT	quadruple therapy +	g quadruple	31	32	96.9%	96.8%	NA	Chen <i>et</i>
<i>butyricum</i>		inactivated <i>C.</i>	therapy						<i>al.</i> ⁷
		<i>butyricum</i>							
		Standard triple	Standard triple						
<i>Saccharomyces</i>	Meta	therapy, bismuth-	therapy, bismuth-						
<i>boulardii</i>	analysis	quadruple therapy, or	quadruple therapy,	1532	1508	81.8%	74.3%	NA	Zhou <i>et</i>
		sequential therapy + <i>S</i>	or sequential						<i>al.</i> ⁸
		<i>boulardi</i>	therapy with or						
			without placebo						
<i>Bifidobacterium</i>	RCT	Bismuth-containing	Bismuth-containin	NA	NA	NA	NA	3.73	Jiang <i>et</i>

		conventional	g conventional						(2.79,5.0	al. ⁹
		quadruple therapy +	quadruple therapy						0)	
		<i>Bifidobacterium</i>								
		Bismuth-containing	Bismuth-containin							He <i>et</i>
	RCT	quadruple therapy +	g quadruple	120	116	91.7%	92.2%	NA		al. ¹⁰
<i>Enterococcus</i>	RCT	<i>Bifidobacterium</i>	therapy + placebo							
		Standard triple	Standard triple							Kakiuchi
		therapy +	therapy	35	31	94.1%	83.9%	NA		<i>et al.</i> ¹¹
		<i>Enterococcus</i>								

NA, not applicable.

Reference

1. Yu M, Zhang R, Ni P, *et al.* Efficacy of Lactobacillus-supplemented triple therapy for H. pylori eradication: A meta-analysis of randomized controlled trials. *PLoS One* 2019;14(10):e0223309.
2. Medeiros JA, Gonçalves TM, Boyanova L, *et al.* Evaluation of Helicobacter pylori eradication by triple therapy plus Lactobacillus acidophilus compared to triple therapy alone. *Eur J Clin Microbiol Infect Dis* 2011;30(4):555-559.
3. Canducci F, Armuzzi A, Cremonini F, *et al.* A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. *Aliment Pharmacol Ther* 2000;14(12):1625-1629.
4. Li M, Wang X, Dong X, *et al.* Lactobacillus reuteri compared with placebo as an adjuvant in Helicobacter pylori eradication therapy: a meta-analysis of randomized controlled trials. *Therap Adv Gastroenterol* 2024;17:17562848241258021.
5. Sahagún-Flores JE, López-Peña LS, de la Cruz-Ramírez Jaimes J, *et al.* Erradicación de helicobácter pylori: esquema triple tradicional versus mismo esquema más probiótico [Eradication of Helicobacter pylori: triple treatment scheme plus Lactobacillus vs. triple treatment alone]. *Cir Cir* 2007;75(5):333-336.

6. Tursi A, Brandimarte G, Giorgetti GM, *et al.* Effect of Lactobacillus casei supplementation on the effectiveness and tolerability of a new second-line 10-day quadruple therapy after failure of a first attempt to cure Helicobacter pylori infection. *Med Sci Monit* 2004;10(12):CR662-666.
7. Chen L, Xu W, Lee A, *et al.* The impact of Helicobacter pylori infection, eradication therapy and probiotic supplementation on gut microenvironment homeostasis: An open-label, randomized clinical trial. *EBioMedicine* 2018;35:87-96.
8. Zhou BG, Chen LX, Li B, *et al.* Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: A systematic review and meta-analysis with trial sequential analysis. *Helicobacter* 2019;24(5):e12651.
9. Jiang X, Xu C, Liu B, *et al.* Efficacy and safety of bifidobacterium quadruple viable tablets in the treatment of Helicobacter pylori-infected peptic ulcer or gastritis patients: a systematic review and meta-analysis. *BMC Infect Dis* 2023;23(1):313.
10. He C, Xie Y, Zhu Y, *et al.* Probiotics modulate gastrointestinal microbiota after Helicobacter pylori eradication: A multicenter randomized double-blind placebo-controlled trial. *Front Immunol.* 2022;13:1033063.

11. Kakiuchi T, Mizoe A, Yamamoto K, *et al.* Effect of probiotics during vonoprazan-containing triple therapy on gut microbiota in *Helicobacter pylori* infection: A randomized controlled trial. *Helicobacter* 2020;25(3):e12690.